3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Ovarian Neoplasms
10
Fallopian Tube Neoplasms
10
Breast Neoplasms
7
Endometrial Neoplasms
5
Neoplasms
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Metastatic Castration-resistant Prostate Cancer
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Cholangiocarcinoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Interventions
olaparib
1
lutetium Lu 177 dotatate
1
enasidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esthesioneuroblastoma, Olfactory
×
olaparib
×
30 days
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled